Dr. Cigall Kadoch Ph.D. is the Founder & Director at Foghorn Therapeutics.
As the Founder & Director of Foghorn Therapeutics, the total compensation of Dr D at Foghorn Therapeutics is 225,000$. There are 3 executives at Foghorn Therapeutics getting paid more, with Dr. Carl Peter Decicco Ph.D. having the highest compensation of 676,240$.
Dr D is 35, he's been the Founder & Director of Foghorn Therapeutics since . There are 7 older and no younger executives at Foghorn Therapeutics. The oldest executive at Foghorn Therapeutics Inc. is Dr. Douglas G. Cole M.D., 61, who is the Founder & Chairman.
Cigall's mailing address filed with the SEC is 500 TECHNOLOGY SQUARE, STE 700, CAMBRIDGE, MA, 02139.
Over the last 4 years, insiders at Foghorn Therapeutics have traded over 262,160$ worth of Foghorn Therapeutics stock and bought 305,500 units worth 4,888,000$ . The most active insiders traders include Adam Koppel、Ian F Smith、B Lynne Parshall. On average, Foghorn Therapeutics executives and independent directors trade stock every 109 days with the average trade being worth of 663,343$. The most recent stock trade was executed by Steven F. Bellon on 9 September 2024, trading 20,000 units of FHTX stock currently worth 190,000$.
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia; and FHD-609, a small molecule protein degrader of BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. Foghorn Therapeutics Inc. has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel therapeutics based on disruptors of a specified transcription factor target. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Foghorn Therapeutics executives and other stock owners filed with the SEC include: